NCT04885361 - To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

March 31, 2022

Conditions

Coronavirus Disease (COVID-19)

Interventions

BIOLOGICAL

CoVepiT (OSE13E)

Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.

Trial Locations (1)

RECRUITING

Center for Vaccinology (CEVAC),, Ghent